Lv11
40 积分 2024-09-28 加入
Baseline 18F-FDG PET Radiomics Predicting Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma after R-CHOP (-Like) Therapy
4小时前
已完结
International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma
25天前
已关闭
Interim FDG-PET/CT for Response Assessment of Lymphoma
2个月前
已完结
Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice
2个月前
已完结
Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy
2个月前
已完结
Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy
2个月前
已关闭
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
2个月前
已完结
International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma
2个月前
已关闭
DLBCL: Who is high risk and how should treatment be optimized?
2个月前
已完结
DLBCL: Who is high risk and how should treatment be optimized?
2个月前
已关闭
皖公网安备34019202002308
